Status and phase
Conditions
Treatments
About
To assess the dose proportionality of azithromycin concentrations and toleration when delivered in tablet formulation to HIV-infected patients.
The need exists to further assess the antibacterial agent azithromycin at differing doses in an HIV-infected population.
Full description
The need exists to further assess the antibacterial agent azithromycin at differing doses in an HIV-infected population.
Patients are randomized to receive azithromycin at 1 of 2 doses in a two-treatment, two-period, cross-over study. Dosing visits are separated by at least 14-day wash-out periods.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Patients must have:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Patients with the following prior condition are excluded:
Clinically important change in baseline status within 4 weeks prior to study entry.
Prior Medication:
Excluded:
Known drug or alcohol dependence.
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal